This Article Full Text Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by SoRelle, R. Search for Related Content PubMed Articles by SoRelle, R.

(Circulation. 2002;106:e9010.)
© 2002 American Heart Association, Inc.

Cardiovascular News

Ruth SoRelle, MPH

Circulation Newswriter

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Rosiglitazone (Avandia) Affects More Than Insulin Resistance

Six months of treatment with rosiglitazone (Avandia) appears to have lowered some inflammatory markers of cardiovascular disease and/or myocardial infarction risk, according to researchers from the University of Texas at San Antonio, Tufts-New England Medical Center in Boston, Mass, and GlaxoSmithKline, the maker of Avandia, who published their research in this week’s issue of Circulation (Circulation. 2002;106:679–684).

The researchers noted that after 26 weeks of treatment with rosiglitazone, patients’ serum showed a statistically significant reduction of the mean levels of C-reactive protein, matrix metalloproteinase-9 (which has been implicated in plaque rupture), and white blood cells. Reduction of interleukin-6, another marker considered, was small and not much different from placebo groups. The researchers, led by Steven M. Haffner, MD, of the University of Texas Health Science Center at San Antonio, concluded that rosiglitazone has an overall beneficial effect on the risk of cardiovascular disease because it reduces blood levels of matrix metalloproteinase-9 and C-reactive protein—both markers for heart disease risk.

Coronary Vascular Endothelial Dysfunction Has Prognostic Value
Impaired vascular endothelial function appears to be associated with an increased risk of cardiovascular events, such as death from heart disease, myocardial infarction, stroke, and unstable angina, according to researchers from the Cardiology Branch and the Office of Biostatistics Research at the National Heart, Lung, and Blood Institute in a report in this week’s issue of Circulation (Circulation. 2002;106:653–658).

The scientists, led by Julian P.J. Halcox, MA, MRCP, measured changes in coronary vascular resistance, epicardial diameter, endothelium-dependent function, and endothelium-independent vascular function in 308 patients who were . . . [Full Text of this Article]